This trial will offer psilocybin therapy in a group setting with a decreased therapist to subject ratio in order to assess feasibility. Seven group therapy sessions will include prep, psilocybin, and integration sessions occurring on a weekly basis.
11 Primary · 0 Secondary · Reporting Duration: 18 months
Consent of patients with a cancer diagnosis or hematologic malignancy
Enrollment of patients with a cancer diagnosis or hematologic malignancy
recruitment of patients with cancer diagnosis or hematologic malignancy
Number of adverse events (AEs) and serious adverse events (SAEs) characterized by duration
Number of adverse events (AEs) and serious adverse events (SAEs) characterized by duration.
Number of adverse events (AEs) and serious adverse events (SAEs) characterized by relationship to study treatment.
Number of adverse events (AEs) and serious adverse events (SAEs) characterized by seriousness
Number of adverse events (AEs) and serious adverse events (SAEs) characterized by seriousness.
Number of adverse events (AEs) and serious adverse events (SAEs) characterized by severity
Number of adverse events (AEs) and serious adverse events (SAEs) characterized by type
Number of adverse events (AEs) and serious adverse events (SAEs) characterized by type.
Side Effects for
7%Viral upper resp. tract infection
4%Alcohol withdrawal syndrome
4%Lower resp. tract congestion
2%Influenza like Illness
2%Traumatic lung injury
2%Pain in extremity
This histogram enumerates side effects from a completed 2021 Phase 2 trial (NCT02061293) in the Diphenhydramine ARM group. Side effects include: Nausea with 9%, Pain with 7%, Bronchitis with 7%, Viral upper resp. tract infection with 7%, Back pain with 7%.
1 Treatment Group
Treatment: all patients
1 of 1
12 Total Participants · 1 Treatment Group
Primary Treatment: Psilocybin · No Placebo Group · Phase < 1
Treatment: all patients
DrugExperimental Group · 1 Intervention: Psilocybin · Intervention Types: Drug
Drug Approval Stage
How many patients have taken this drug
Not yet FDA approved
Screening: ~3 weeks
Reporting: 18 months
Who is running the clinical trial?
University of UtahLead Sponsor
1,008 Previous Clinical Trials
1,787,370 Total Patients Enrolled
11 Previous Clinical Trials
482 Total Patients Enrolled
Anna Beck, MDPrincipal InvestigatorHuntsman Cancer Institute
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
I can speak English fluently.
The patient has a very good performance status.
Volunteers must have a high school or equivalent level of education in order to participate in the study
A person aged ≥ 25 years old, either male or female.
Someone who has been diagnosed with cancer and is currently undergoing treatment or has completed treatment within the last 26 weeks is eligible to participate in this study.
Your pet has a life expectancy of 3 months or more.
The subject should have a support person to escort them home after taking psilocybin.
The subject is able to provide consent and is willing to sign an approved consent form.
A depression disorder, including an adjustment disorder with disturbance of mood, is currently diagnosed using DSM-V.
Not taking medication to treat depression and/or anxiety for at least 4 weeks prior to initiation of the study.
Who else is applying?
What state do they live in?
How old are they?
|18 - 65||71.4%|
What site did they apply to?
|Huntsman Cancer Institute||100.0%|
What portion of applicants met pre-screening criteria?
|Did not meet criteria||14.3%|
How responsive is this trial?
Typically responds via
Most responsive sites:
- Huntsman Cancer Institute: < 24 hours
Average response time
- < 1 Day